Intercalary allograft reconstruction following femoral tumour resection: mid- and long-term results and benefits of adding a vascularised fibula autograft

Vincent Crenn\textsuperscript{1,2*}, Yonis Quinette\textsuperscript{1}, Charlie Bouthors\textsuperscript{3}, Gilles Missenard\textsuperscript{3}, Brice Viard\textsuperscript{3}, Philippe Anract\textsuperscript{4}, Stéphane Boisgard\textsuperscript{5}, Eric Mascard\textsuperscript{6}, François Gouin\textsuperscript{1,2,7} and The Société d’Orthopédie de l’Ouest

Abstract

Purpose: Bone healing in femoral reconstructions using intercalary allografts can be compromised in a tumour context. There is also a high revision rate for non-union, infection, and fractures in this context. The advantages and disadvantages of an associated vascularised fibula graft (VFG) are still a matter of debate.

Methods: In a multicentre study, we retrospectively analysed 46 allograft reconstructions, operated on between 1984 and 2017, of which 18 were associated with a VFG (VFG\textsuperscript{+}) and 28 without (VFG\textsuperscript{−}), with a minimum follow-up of 2 years. We determined the cumulative probability of bone union as well as the mid- and long-term revision risks for both categories by Kaplan-Meier survival analysis and a multivariate Cox model. We also compared the MSTS scores.

Results: Significant differences in favour of VFG\textsuperscript{+} reconstruction were observed in the survival analyses for the probability of bone union (log-rank, $p = 0.017$) and in mid- and long-term revisions (log-rank, $p = 0.032$). No significant difference was observed for the MSTS, with a mean MSTS of 27.6 in our overall cohort ($p = 0.060$). The multivariate Cox model confirmed that VFG\textsuperscript{+} was the main positive factor for bone union, and it identified irradiated allografts as a major risk factor for the occurrence of mid- and long-term revisions.

Conclusion: Bone union was achieved earlier in both survival and Cox model analyses for the VFG\textsuperscript{+} group. It also reduced the mid- and long-term revision risk, except when an irradiated allograft was used. In case of a tumour, we thus recommend using VFG\textsuperscript{+} from a fresh-frozen allograft, as it appears to be a more reliable long-term option.

Keywords: Intercalary allograft, Vascularised fibula graft, Bone tumour, Bone reconstruction

Introduction

The femur is a common site for primary bone tumours, but a diaphyseal location is less common than at the extremities [1]. Several techniques have been described for reconstruction after extensive diaphyseal femoral resection (> 10 cm) [2]: biological reconstructions: vascularised autograft [3], Masquelet’s induced membrane [4], allograft [5], combined graft [6], or even distraction osteogenesis or transport techniques [7], and finally prosthetic reconstructions using segmental prostheses, or custom reconstructions [8–11]. Some other innovative biologic techniques are also described but with a short follow-up on a small cohort [12]. Intercalary prostheses require a large residual bone segment to secure their stems and are, therefore, limited by the extent of the resection. Moreover, long-term survival is...
questionable with these implants. Although they allow early weight-bearing, the rate of complications is high (up to 60%), consisting primarily of infections, fractures, and loosening [11, 13]. Several authors also report the use of devitalised tumour-bearing bone with interesting results, but with tumour histological analysis potential issues [14–16]. Vascularised fibular autograft reconstructions alone are mainly used in children, with encouraging results, but the non-weight-bearing period, which is necessary for graft hypertrophy and consolidation, is long and significantly at risk of fracture (up to 15%) [17, 18]. This technique also has additional morbidity due to the second surgical site [19, 20]. In adults, allograft reconstructions, commonly used in extensive diaphyseal reconstructions, are favoured. Their mechanical qualities are similar to those of normal bone, with the possibility of using a graft of the same bone and with a similar calibre, albeit with a risk of non-union, fatigue fracture due to the lack of integration, or even resorption [21].

It is common for an autograft to be associated with the femoral allograft. This can be a vascularised fibula graft (VFG) [22–24] or other types of bone graft such as a rectangular cortical cancellous tibial graft (TG) [25] or a cancellous iliac crest graft (ICG). There are many ways to stabilise the allograft as well as ways to prepare and conserve the allograft (irradiated, fresh-frozen) [2, 26, 27]. The ideal approach has to be established in terms of bone union rates, revisions, and functional outcomes, especially after substantial follow-up. Ultimately, although the indications for intercalary allograft femoral reconstructions are increasingly standardised, the use of an associated graft is still debatable. This subject is particularly critical for the femur, which is a bone that is subject to pronounced compressional stress and rotational constraints. Since it concerns young patients with long life expectancies, it is essential that this specific topic is evaluated in mid- and long-term follow-up.

Our hypothesis is that adding a VFG may improve bone healing and the longevity results of allograft reconstructions in femoral resections. Therefore, we analysed whether adding a VFG (1) improved bone healing and (2) limited the rate of mid- and late-term revisions. We also sought to determine the functional impact of a VFG in this context. In addition, a multivariate analysis was carried out to identify whether other factors, such as the stabilisation modalities or the type of allograft, influence bone union and mid/late-term revisions.

Materials and methods

Patients

This retrospective study was conducted in four French hospitals specialised in oncological orthopaedic surgery, as part of the work resulting from the topic on allografts at the symposium of the French Society of Orthopaedic and Trauma Surgery. All consecutive whole-circumference resections of primary tumours in the long bones that were reconstructed with an intercalary allograft of at least 10 cm were included and reviewed retrospectively. Patients operated on between October 1984 and February 2015 with a minimum follow-up of 2 years were included. Patients with epiphysis or joint invasion were excluded.

Methods

Allografts were harvested under sterile conditions during post-mortem tissue donation and were stored at −80 °C by our dedicated bone banks. The allografts were fresh-frozen or irradiated. All of the patients received periorative antibiotics according to the relevant protocols.

During the surgical tumour excision, the femoral allograft was kept in a saline solution containing antibiotics. The patients also received intraoperative intravenous antibiotic prophylaxis. The allografts were prepared using cryopreservation or irradiation and freezing. All of the resections spared the articular surface, with preservation of the epiphysis.

In the case of an associated VFG, the fibula was harvested in a standard manner by a second team using a lateral approach from the contralateral limb. The pedicle was then anastomosed termino-laterally on the artery and femoral vein. Depending on the case, the VFG could either be affixed with screws or embedded in the allograft (Fig. 1). In cases that did not involve an associated VFG, a tibial graft (TG) was harvested at the same time, on the homo- or contralateral side. A cancellous bone graft (CBG) from the iliac crest or reaming product was also an option associated with the allograft.

Evaluation methods

The aim of this study was to assess the impact of adding a VFG. Therefore, the main objective was to study the bone-healing time, and the primary criterion was defined by a cortical union of at least 75%, as analysed on standard X-rays. If the assessment of union was inconclusive on conventional X-rays, the union was assessed using computed tomography (CT). Surgical intervention to facilitate the union of osseous junctions in Henderson type 2 complications, at least 6 months after the primary surgery, was defined as non-union.

The secondary criteria comprised mid- and long-term revisions (occurring after 2 years of follow-up), defined as any surgical revision at the surgical site of the allograft reconstruction, excluding oncological resection. These complications were investigated according to the modified Henderson classification of ISOLS [28]. We also analysed the functional results, based on the MSTS scores.
[29], and we applied a multivariate Cox model to bone union and mid- and long-term revision to assess other variables.

Statistics and ethics
The statistical analyses were carried out using the IBM SPSS Statistics V19 software. The survival analyses were conducted using the Kaplan-Meier method, with comparisons based on the log-rank test [30]. Univariate and multivariate Cox proportional hazard regression analyses were used and performed with a stepwise forward conditional method. Comparative analysis of the data between the subgroups was conducted using the chi² or Fisher’s exact tests and Student’s t-test. The threshold for significance was $p < 0.05$. The institutional review board approved the protocol. In keeping with

![Fig. 1 Vascularised fibula embedded in the femoral allograft before implantation. The allograft window allows vascular anastomosis according to the Capanna technique [15].](image1)

![Fig. 2 Study flowchart](image2)
| Table 1 | Description of the population of the entire cohort and comparison of the qualitative data between the VFG+ and VFG− subgroups using the chi² or Fisher’s exact test and for the quantitative data the t-test |
|---------|---------------------------------------------------------------------------------|
| Cohort, n = 46 | VFG+, n = 18 (39.1%) | VFG−, n = 28 (60.9%) | p-value |
| **Demographic data** | | | |
| Age (years) | 20.9 (7–62) | 19.6 (7–48) | 21.7 (9–62) | 0.553 |
| Male | 16 (34.8%) | 8 (44.4%) | 8 (28.6%) | 0.270 |
| Female | 30 (65.2%) | 10 (55.6%) | 20 (71.4%) | |
| Follow-up (months) | 132.7 (24–402) | 114.9 (37–233) | 145.8 (24–402) | 0.250 |
| Resection length (mm) | 198 (100–340) | 190 (140–260) | 203 (100–300) | 0.395 |
| **Diagnosis** | | | 0.088 |
| Osteosarcoma | 26 (56.5%) | 9 (50.0%) | 17 (60.7%) | |
| Ewing’s sarcoma | 11 (23.9%) | 7 (38.9%) | 4 (14.3%) | |
| Chondrosarcoma | 5 (10.9%) | 0 (0.0%) | 5 (17.9%) | |
| Others a | 4 (8.7%) | 2 (11.1%) | 2 (7.1%) | |
| **Associated therapies** | | | |
| Adjuvant chemotherapy | 35 (76.1%) | 16 (88.9%) | 19 (67.9%) | 0.160 |
| Adjuvant radiotherapy | 4 (8.7%) | 2 (11.1%) | 2 (7.1%) | 0.639 |
| **Allograft preparation** | | | 0.022 |
| Irradiated | 14 (30.4%) | 2 (11.1%) | 12 (42.9%) | |
| Fresh-frozen | 32 (69.6%) | 16 (88.9%) | 16 (57.1%) | |
| **Stabilisation device** | | | < 0.001 |
| Nail | 12 (26.1%) | 9 (50.0%) | 3 (10.7%) | |
| Bridging plate | 17 (37.0%) | 9 (50.0%) | 8 (28.6%) | |
| Nail + plate | 17 (37.0%) | 0 (0.0%) | 17 (60.7%) | |
| a In the VFG group: one fibrosarcoma, one undifferentiated carcinoma; in the no VFG group: one clear cell renal carcinoma, one haemangioendothelioma |

| Table 2 | Description of the population based on the postoperative follow-up data and comparison of the qualitative data between the VFG+ and VFG− subgroups using the chi² or Fisher’s exact test and the quantitative data using the t-test |
|---------|---------------------------------------------------------------------------------|
| Cohort, n = 46 | VFG+, n = 18 (39.1%) | VFG−, n = 28 (60.9%) | p-value |
| **Revision surgery** | | | 0.116 |
| n = 0 | 19 (41.3%) | 10 (55.6%) | 9 (32.1%) | |
| n = 1; 2 | 15 (32.6%) | 5 (27.8%) | 10 (35.8%) | |
| n ≥ 3 | 12 (26.1%) | 3 (16.6%) | 9 (32.1%) | |
| **Allograft resorption (ISOLS)** | | | 0.032 |
| 1, excellent; 2, good | 39 (84.8%) | 18 (100%) | 21 (75.0%) | |
| 3, fair; 4, poor | 7 (15.2%) | 0 (0.0%) | 7 (25.0%) | |
| **Complications** | | | |
| Henderson 1 | 1 (2.2%) | 1 (5.6%) | 0 (0.0%) | 0.391 |
| Henderson 2 | 17 (37.0%) | 6 (33.3%) | 11 (39.3%) | 0.683 |
| Henderson 3 | 9 (19.6%) | 2 (11.1%) | 7 (25%) | 0.448 |
| Henderson 4 | 3 (6.5%) | 1 (5.6%) | 2 (7.1%) | 1 |
| Allograft removal a | 2 (4.3%) | 1 (5.6%) | 1 (3.6%) | |
| **Bone union** | | | |
| Healed at last follow-up | 43 (93.5%) | 17 (94.4%) | 26 (92.9%) | 1 |
| Healed with no revision | 28 (60.9%) | 12 (66.7%) | 16 (57.1%) | 0.578 |
| Mean bone union delay (months) | 21.8 (4–120) | 12.6 (5–34) | 27.9 (5–120) | 0.012 |
| **Functional score** | | | 0.060 |
| MSTS (/30) (n = 44) | 27.3 (18–30) | 26.3 (21–30) | 28 (18–30) | |
| a Excluding oncological causes |
French legislation regarding retrospective anonymised study data (articles L.1121-1 paragraph 1 and R1121-2, Public Health Code), Nantes University Hospital confirmed that approval from the ethics committee was not required given the non-interventional nature of the study, and no ethics committee approval was required at the time that the study was started. The database was anonymised, and all of the patients provided their verbal consent and received an information document.

**Results**

Of the 78 patients operated on for an intercalary allograft reconstruction, 46 patients were included: 18 (39.1%) were operated on with VFG (VFG+) and 28 (60.9%) with no VFG (VFG−) (Fig. 2).

The average follow-up was 132.7 months, with the follow-up exceeding 10 years for 15 patients (32.6%) and 25 years for 3 patients (6.5%). No significant difference in the follow-up was noted between the VFG+ group and the VFG− group (114.9 months (37–233) vs. 145.8 months (24–402), P = 0.25) (Table 1). The VFG− group comprised two other graft modalities: 19 associated TG (67.9%) and 9 CBG (32.1%).

There were significantly more irradiated allografts in the VFG− group compared to the VFG+ group (12 (42.9%) vs. 2 (11.1%); P = 0.022). Lastly, the resorption scores according to the ISOLS classification were significantly worse in the VFG− group, with 25% of the patients being scored 3 or 4 compared to 0% in the VFG+ group (P = 0.032) (Table 2).

Two patients (4.3%) required allograft removal for non-oncological reasons. One (3.6%, VFG− group) underwent amputation due to septic complications 36 months postoperatively, and they died of oncological disease; another patient (5.6%, VFG+ group) required allograft removal and arthrodesis for an allograft fracture in non-union at 107 months of follow-up. We identified two specific complications of fibular harvesting: compartment syndrome requiring aponeurotomy at day 1 and an acquired toe claw that necessitated tendon lengthening surgery.

The overall bone union rate for the cohort at the last follow-up was 93.5%, with 43 patients healed out of 46, and the median bone union rate was 18.0 (95% CI, 13.6 to 22.4%) (Fig. 3A).

Using the log-rank test, a significant difference was observed between the VFG+ group and the VFG− group (P = 0.017). At 2 years, all but one of the patients achieved bone fusion (n = 17/18, 94.4%, 95% CI, 62.7 to 99.2%) in the VFG+ group, and nine had not yet healed in the VFG− group (n = 19/28, 67.9%, 95% CI, 45.0 to 81.3%).

Regarding mid- and late-term revisions, by excluding occurrences in the first 2 years of follow-up, the revision rate was significantly lower in the VFG+ group (log-rank test, P = 0.034) (Fig. 3B). In this situation, we observed a significant difference, with 100% 5-year survival for the VFG+ group vs. 71.2% (95% CI, 55.0 to 92.1%) for the VFG− group and 15- and 20-year survival rates of 81.5% (95% CI, 77.3 to 100%) vs. 45.6% (95% CI, 25.1 to 82.6%), respectively.

In the VFG+ group, two revisions were necessary: a nail material replacement (Henderson type 3) and an allograft fracture on non-union (Henderson types 2 and 3). In the VFG− group, 10 revisions were necessary, 50% of them for non-union (Henderson type 2) (one of them was successfully healed by the addition of a VFG at 106 months), 30% for stabilisation device failure or modification (Henderson type 3), and 20% for chronic infection (Henderson type 4) (one of them requiring allograft removal at 36 months).

For the overall cohort survival rate at 1 year, the rate of allograft revision was 67.4% (95% CI, 55.1 to 82.4%) excluding oncological causes (Additional file 1: Fig. S1).

Early revisions before 1 year of follow-up occurred in 10 patients (35.7%) in the VFG− group, compared to 4 patients (22.2%) in the VFG+ group (P = 0.512). Before 2 years of follow-up, revisions occurred in 14 patients (50%) in the VFG− group, compared to 6 patients in the VFG+ group (33.3%) (Fischer test, P = 0.364).

For the MSTS scores, we observed a mean MSTS score of 27.3 (18–30) in the cohort. The mean MSTS score was slightly lower in the VFG+ group than in the VFG− group (26.3 (21–30) vs. 28.0 (18–30); P = 0.060) (Fig. 4).

Cox model univariate analysis was performed for bone union, and it showed that VFG was a positive factor for the probability of bone healing, with a hazard ratio (HR) of 2.64 (95% CI, 1.28–5.44), P = 0.008. In the multivariate model analysis, VFG+ was again the most significant.
Fig. 3 (See legend on previous page.)
independent variable, with an HR of 6.53 (95% CI, 2.16–19.61), \( p = 0.001 \), while adjuvant radiotherapy was identified as a negative impact variable with an HR of 0.21 (95% CI, 0.06–0.74), \( p = 0.015 \) (Table 3).

Regarding the revisions occurring after 2 years of follow-up, irradiated allografts were significantly more revised after 2 years in the univariate analysis, with an HR of 3.57 (95% CI, 1.12–11.48), \( p = 0.031 \). VFG+ was significantly associated with a lower revision risk and an associated HR of 0.17 (95% CI, 0.04–0.80), \( p = 0.024 \). However, in the multivariate analysis model, there were only two significant variables: adjuvant radiotherapy, with an HR of 5.91 (95% CI, 1.49–24.22), \( p = 0.012 \) (Table 3).

**Discussion**

Regarding bone union, we observed a significantly higher union rate by Kaplan-Meier survival analysis for VFG+ compared to VFG− allografts (log-rank, \( p = 0.017 \)). The median bone union rate was 12.0 months for the VFG+ group and 20.0 months for the VFG− group. This observation is in accordance with the multivariate analysis model, in which the vascularised fibula graft was the most significant variable linked to the bone union, with an HR of 3.81, \( p = 0.001 \). These results appear to be in line with the data in the literature: in their study of 11 reconstructions by allograft and vascularised fibula, Ogura et al. found a bone union in 91% of cases, with a mean time to union of 9.9 months [31], and Frisoni et al. also reported that a vascularised autograft can be a protective factor against delayed union [32].

In intercalary reconstruction analysis efficiency analyses, bone union delay and occurrence were critical, allowing full weight-bearing and decreasing the risk of revision for Henderson type 2 complications. For this objective, an associated VFG appeared to have a positive effect on our population. Devitalised bone grafts, using various methods (irradiated, alcohol inactivated, autoclaved tumour bearing bone) reported similar bone union healing delay in the literature, ranging from 11 to 14 months [14–16].

After the first 2 years of follow-up, in the mid- and long-term, once most early complications have occurred [33, 34], revisions were significantly less frequent in the survival analysis in the VFG+ group (log-rank, \( p = 0.034 \)). These results were not confirmed; however, in our multivariate Cox model analysis, in which the use of an irradiated allograft (HR=6.00, \( p = 0.012 \)) was the most significant independent variable and appeared to have a more pronounced effect on mid- and late-term revision risk. It should be noted that almost half of the TG associated in the VFG− group were performed using an irradiated allograft, and this might thus be a confounding factor, impeding the TG association results. Negative results associated with irradiation preparation are in line with previous concerns that revealed higher failure rates for irradiated compared to non-irradiated allografts, especially with tendinous structures, such as Achilles tendon [35] or anterior cruciate ligament reconstructions.
For diaphyseal allograft indications, the review by Costain and Crawford observed a trend in favour of fresh-frozen allografts, with fewer structural failures, albeit without a clear or strong significance [37]. Therefore, our study confirms this tendency and objectifies significantly more revision rates and allograft resorptions with irradiated allografts in intercalary femoral reconstructions. Allograft long-term resorption issues, as mentioned by several authors, may be an explanation for this mid- and late-term revision difference [38], as we found with the greater resorption risk.

In light of our results, we recommend avoiding the use of irradiated allografts in this indication. It appears to be safer to use a fresh-frozen allograft, as an irradiated allograft may have impeded the long-term allograft structural reliability in our study, with more Henderson type 3 complications (allograft or material fractures), higher revision rates, and higher resorption rates.

Not surprisingly, adjuvant radiation therapy appeared to have a significant negative effect on bone union and mid- and late-term revision rates in the multivariate model (with HRs of 0.21, \( p = 0.015 \) and 5.91, \( p = 0.030 \), respectively). Its negative role has been well described in the literature, with higher septic complications and non-unions [39]. For Aponte-Tinao et al., radiation therapy is an allograft contraindication, and they hence perform intercalary endoprostheses procedures in these cases [27]. Likewise, bridging plates can improve bone union, and they resulted in the greatest effect for less mid- and long-term revision in our univariate analysis, albeit without significance (Fig. 5). This result is in keeping with preclinical and human models, which consistently demonstrate the importance of rigid fixation in the allograft–host junction [40].

The functional results were satisfactory in our cohort, with an average MSTS score of 27.3 at the last follow-up (18–30). Likewise, Aponte-Tinao et al. observed a score of 27.0 at 68 months in a cohort of 83 femoral intercalary allografts [33]. The MSTS scores for VFG+ were slightly lower than for VFG−, but the difference was not significant: 26.3 (21–30) vs. 28.0 (18–30), respectively, \( p = 0.060 \). This trend may reflect the inherent iatrogenicity of

### Table 3
Univariate and multivariate (stepwise forward conditional method) Cox model regression for allograft bone union and revisions after 2 years of follow-up

|                             | Bone union, HRa (95.0% CI) | p-value | > 2 years revisions, HRa (95.0% CI) | p-value |
|-----------------------------|----------------------------|---------|-------------------------------------|---------|
| **Univariate analysis**     |                            |         |                                     |         |
| Gender (male)               | 1.06 (0.56–1.99)           | 0.860   | 1.29 (0.38–4.32)                    | 0.672   |
| Age (years)                 | 0.99 (0.96–1.02)           | 0.460   | 1.01 (0.9–1.05)                     | 0.790   |
| Resection length (mm)b      | 1.00 (0.94–1.06)           | 0.967   | 0.98 (0.87–1.10)                    | 0.705   |
| Irradiated allograft        | 0.68 (0.35–1.32)           | 0.256   | 3.57 (1.12–11.48)                   | 0.031   |
| Adjuvant radiotherapy       | 0.32 (0.09–1.05)           | 0.061   | 2.63 (0.72–9.71)                    | 0.144   |
| Adjuvant chemotherapy       | 1.05 (0.51–2.14)           | 0.894   | 1.10 (0.33–3.55)                    | 0.759   |
| Diagnosisc                  |                            |         |                                     |         |
| CHS (ref)                   | 0.841                      |         |                                     |         |
| OS                          | 0.75 (0.28–1.98)           | 0.556   | 0.48 (0.14–1.67)                    | 0.251   |
| Ewing’s                     | 0.84 (0.29–2.43)           | 0.742   | 1.20 (0.14–11.11)                   | 0.866   |
| Associated graft VFG−: TG  | 0.026                      |         |                                     | 0.025   |
| CBG                         | 1.98 (0.85–4.49)           | 0.112   | 0.25 (0.03–2.00)                    | 0.192   |
| VFG+                        | 2.64 (1.28–5.44)           | 0.008   | 0.17 (0.04–0.80)                    | 0.024   |
| Stabilisation               |                            |         |                                     |         |
| Nail (ref)                  | 0.149                      |         |                                     | 0.095   |
| Plate                       | 1.17 (0.54–2.51)           | 0.690   | 0.79 (0.13–4.98)                    | 0.814   |
| Nail + plate                | 0.59 (0.27–1.30)           | 0.191   | 3.38 (0.83–12.82)                   | 0.090   |
| **Multivariate analysis**   |                            |         |                                     |         |
| Adjuvant RT                 | 0.21 (0.06–0.74)           | 0.015   | 5.91 (1.19–29.38)                   | 0.030   |
| Irradiated allograft        |                            |         | 6.00 (1.49–24.22)                   | 0.012   |
| Associated graft VFG−: TG  | 0.004                      |         |                                     |         |
| CBG                         | 1.89 (0.80–4.44)           | 0.145   |                                     |         |
| VFG+                        | 3.81 (1.68–8.64)           | 0.001   |                                     |         |

a Hazard ratio. b Continuous variable. c Reference variable in a categorical variable ≥ 3 levels.
fibular graft harvesting, as we observed two specific complications. Complications at the fibula harvest site are possible, and they are found in 6% of patients according to Bernd et al. and 20% according to Abed et al. [41, 42]. This may have led to the slightly lower functional score that we observed.

The main complications of this procedure reported in the literature are infection (0–14%), fractures (6–29%), and non-union (13–40%) [1, 43–45]. We did not find that there was a significant difference in the complications between the VFG + group and the VFG − group. We observed a low rate of infections (Henderson type 4) (4.2%) in our entire cohort, while the literature reports rates of 5 to 18% in cases of allografts alone and 0 to 16% in cases of hybrid transplants [19, 46–48]. Since our study focused only on femoral reconstructions; this may explain why there were fewer infections than in studies that included tibial reconstructions, which are more prone to this type of complication. The Henderson type 2 and 3 complications were similar to those reported in the literature.

Despite the large number of cases, the homogeneous anatomical nature of femoral reconstructions and the long follow-up, this study has a number of limitations. Due to the multicentre analysis, this retrospective work can be limited to a certain degree by incomplete or imprecise documentation of postoperative events. Possible bias may mitigate our results, such as the young age of some of the patients, who could be subject to revisions for specific skeletal growth problems or who might have allograft bone union particularities [26]. As a retrospective study, there was no randomisation, and treatments (VFG+ or VFG−) were assigned depending on the surgeon's preferences and skills. Moreover, statistical analysis might be interpreted with caution due to the small cohort. We chose to focus on mid- and late-term complications to increase the power of our analysis because most early complications may be the result of chemotherapy or radiation therapy, irrespective of the reconstruction choices. Finally, allografts with or without VFG result in comparable oncological outcomes, but they can differ in terms of the functional results as well as revisions and complications, which is why we excluded oncological revisions from our analysis, as suggested by Gundel et al. [49].

Conclusion
Vascularised fibula grafts appear to have a positive effect on survival analysis and the multivariate Cox model, with significantly shorter times to bone union. In the survival analysis, mid- and long-term revisions after 2 years occurred significantly less in the VFG + group, although the use of an irradiated allograft appeared to be a more detrimental confounding factor in our multivariate model, and caution should be taken with this allograft preparation with higher radiological resorption. At the last follow-up, the MSTS scores remained high in our cohort, with a mean score of 27.6. We did not observe a significant difference between our subgroups regarding this outcome. Based on our results, and despite possible fibula harvesting iatrogenicity and complexity, it is advisable to perform a vascularised fibula graft in a fresh-frozen allograft whenever possible. Future directions, such as personalised specific instruments, might be studied to facilitate and optimise intercalary allograft reconstruction using VFG.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12957-022-02650-x.

Acknowledgements
We would like to thank Peggy Ageneau and Julianne Berchoud for their support in the administrative proceedings.

Additional file 1: Figure S1. Kaplan-Meier survival curve with failure defined as allograft revision excluding carcinologic causes. Table S1. Allograft resorption (ISOLS score) depending on the allograft type (fresh-frozen or irradiated), Fisher’s exact test: p = 0.006.
Authors' contributions
Conceptualisation: VC, Y.Q., and F.G. Methodology: VC, Y.Q., and F.G. Formal analysis: VC and Y.Q. Data curation: VC and Y.Q. Investigation: VC, Y.Q., C.B., G.M., B.V., PA., S.B., E.M., and F.G. Writing—review and editing: VC, Y.Q., C.B., G.M., B.V., PA., S.B., E.M., and F.G. All of the authors have read and agreed to the final published version of the manuscript.

Funding
This research received no external funding.

Availability of data and materials
The datasets generated and/or analysed for the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The institutional review board approved the protocol. According to French legislation regarding retrospective studies of anonymised data (articles L.1121-1 paragraph 1 and R1121-2, Public Health Code), Nantes University Hospital confirms that approval from the ethics committee was not needed due to the non-interventional nature of the study, and no review by an ethics committee was necessary at the time the study was started. The requisite processes were undertaken with the “Direction de la Recherche Clinique” (DRC) of the University Hospital of Nantes, France, and the “Commission Nationale de l’Informatique et des Libertés” (CNIL). The database was anonymised, and all of the patients provided their verbal consent and received a document with information pertaining to the study.

Consent for publication
All of the patients provided their oral consent and received a document with information pertaining to the study. All of the data were anonymised.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Service de Chirurgie Orthopédique, CHU de Nantes, Place Alexis Ricordeau, 44000 Nantes, France. 2 INSERM, UMR 1238, Phy-Os, Université de Nantes, Nantes, France. 3 Service de Chirurgie Orthopédique, APHP/CHU Kremlin-Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France. 4 Service de Chirurgie Orthopédique, AP-Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France. 5 Service de Chirurgie Orthopédique, CHU Gabriel Montpied, 58 rue Montalembert, 63000 Clermont-Ferrand, France. 6 Département de Chirurgie Orthopédique Pédiatrique, APHP/Hôpital Necker, 149 rue de Sévres, 75015 Paris, France. 7 Département de Chirurgie, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France.

Received: 15 September 2021 Accepted: 24 May 2022
Published online: 13 June 2022

References
1. Bus MP, Dijkstra PDS, van de Sande M, a J, Taminiau AHM, Schreuder HWB, Jutte PC, van der Geest ICM, Schaap GR, Bramer J a M. Intercalary allograft reconstructions following resection of primary bone tumors: a nationwide multicenter study. J Bone Joint Surg Am. 2014;96(4):e26.
2. Panagopoulos GN, Mavrogenis AF, Mauffrey C, Lesensky J, Angelini A, Megalokonomos PD, et al. Intercalary reconstructions after bone tumor resections: a review of treatments. Eur J Orthop Surg Traumatol. 2017;27(6):737–46.
3. Emori M, Kaya M, Inoue H, Takahashi N, Shimizu J, Mizushima E, et al. Vasculisation fibular grafts for reconstruction of extremity bone defects after resection of bone and soft-tissue tumours: a single institutional study of 49 patients. Bone Jt J. 2017;99–B(9):1237–43.
4. Masquelet AC, Fitousi F, Begg T, Muller GP. Reconstruction of the long bones by the induced membrane and spongy autograft. Ann Chir Plast Esthet. 2000;45(3):346–53.
5. Tang X, Guo W, Yang R. Segmental allograft reconstruction in skeletal defect after limb tumor resection. Zhongguo Xiu Fu Chong J. 2011;19(1):22–4.
6. Demirsal M, Ege T, Kose G, Yurttas Y, Babsozkurt M. Reconstruction of intercalary bone defects following bone tumor resection with segmental bone transport using an Ilizarov circular external fixator. J Orthop Sci Off J Jpn Orthop Assoc. 2014;19(6):1004–11.
7. Ahlmann ER, Menendez LR. Intercalary endoprosthetic reconstruction for diaphyseal bone tumours. J Bone Joint Surg Br. 2006;88(11):1487–91.
8. Lu M, Li Y, Luo Y, Zhang W, Zhou Y, Tu C. Uncemented three-dimensional-printed prosthetic reconstruction for massive bone defects of the proximal tibia. World J Surg Oncol. 2018;16(1):47.
9. Pan P, Wang H, Cai Z, Shen J, Sun W. Revision surgeries for tumor endoprostheses around the knee joint: a mid-long-term follow-up of 20 cases. World J Surg Oncol. 2022;20(1):76.
10. Wang J, An J, Li M, Zhang Y, Lin J, Luo Y, et al. Is three-dimensional-printed custom-made ultra-short stem with a porous structure an acceptable reconstructive alternative in peri-knee metaphysis for the tumorous bone defect? World J Surg Oncol. 2021;19(1):235.
11. Wang L, Luo D, Wu J, Xie K, Guo Y, Gan Y, et al. A clinical study on bone defect reconstruction and functional recovery in benign bone tumors of the lower extremity, treated by bone marrow mesenchymal stem cell rapid screening–enrichment–composite system. World J Surg Oncol. 2021;19(1):98.
12. Aldyami E, Abudu A, Grimer RJ, Carter SR, Tillman RM. Endoprosthetic replacement of diaphyseal bone defects. Long-term results. Int Orthop. 2005;29(1):25–9.
13. Qu H, Guo W, Yang R, Li D, Tang S, Yang Y, et al. Reconstruction of segmental bone defect of long bones after tumor resection by devitalized tumor-bearing bone. World J Surg Oncol. 2015;13(1):262.
14. Xu M, Xu M, Zhang S, Li H, Quichi AI, Yu X, et al. Comparative efficacy of intraoperative extracorporeal irradiated and alcohol-inactivated autograft reimplantation for the management of osteosarcoma—a multicentre retrospective study. World J Surg Oncol. 2021;19(1):157.
15. Pan KL, Chan WH, Ong GB, Premserthil S, Zulkarnaen M, Norilda D, et al. Limb salvage in osteosarcoma using autoclaved tumor-bearing bone. World J Surg Oncol. 2012;10(1):105.
16. Houdek MT, Bayne CO, Bishop AT, Shin AY. The outcome and complications of vascularised fibular grafts. Bone Jt Br. 2017;99–B(8):1348–8.
17. Hilven PH, Bayliess L, Cosker T, Dijkstra PDS, Jutte PC, Lahoda LU, et al. The vascularised fibular graft for limb salvage after bone tumour surgery: a multicentre study. Bone Jt Br. 2015;97–B(8):653–61.
18. Muscolo DL, Ayerza MA, Aponte-Tinao L, Ranalletta M, Abalo E. Intercalary femur and tibia segmental allografts provide an acceptable alternative in reconstructing tumor resections. Clin Orthop. 2004;426:97–102.
19. Ortiz-Cruz E, Gebhardt MC, Jennings LC, Springfield DS, Mankin HJ. The results of transplantation of intercalary allografts after resection of tumors. A long-term follow-up study. J Bone Joint Surg Am. 1997;79(1):97–106.
20. Horanek FJ, Gebhardt MC, Tomford WW, Sorer JJ, Zavatta M, Menzner JP, et al. Factors affecting nonunion of the allograft-host junction. Clin Orthop. 2001;382:87–98.
21. Capanna R, Campanacci DA, Belot N, Beltrami G, Manfrini M, Innocenti M, et al. A new reconstructive technique for intercalary defects of long bones: the association of massive allograft with vascularized fibular autograft. Long-term results and comparison with alternative techniques. Orthop Clin North Am. 2007;38(1):51–60 vi.
22. Miyamoto S, Fujiki M, Setsu N, Kawai A. Simultaneous reconstruction of the bone and vessels for complex femoral defect. World J Surg Oncol. 2016;14(1):291.
24. Combal A, Thuau F, Fouasson-Chailloux A, Arrigoni PP, Baud’huin M, Dutelle F, Crenn V. Preliminary results of the “Capasquelet” technique for managing femoral bone defects—combining a masquelet induced membrane and capanna vascularized fibula with an allograft. J Pers Med. 2021;11(8):774. https://doi.org/10.3390/jpm11080774.

25. Brunet O, Anract P, Bouabid S, Babinet A, Dumaine V, Toméno B, et al. Intercalary defects reconstruction of the femur and tibia after primary malignant bone tumour resection. A series of 13 cases. Orthop Traumatol Surg Res OTSR. 2011;7(5):512–9.

26. Errani C, Alfaro PA, Ponz V, Colangeli M, Donati DM, Manfrini M. Does the addition of a vascularized fibula improve the results of a massive bone allograft alone for intercalary femur reconstruction of malignant bone tumors in children? Clin Orthop Related Res. 2021;479(6):1296–308. https://doi.org/10.1097/CORR.0000000000001639.

27. Aponte-Tinajo LA, Ayerza MA, Albergo JI, Farfalli GL. Do massive allograft reconstructions for tumors of the femur and tibia survive 10 or more years after implantation? Clin Orthop. 2020;478(3):17–24.

28. Henderson ER, O’Connor MI, Ruggieri P, Windhager R, Funovics PT, Gibbons CL, et al. Classification of failure of limb salvage after reconstructive surgery for bone tumors: a modified system including biological and expandable reconstructions. Bone Jt J. 2014;96-B(11):1436–40.

29. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop. 1993;286:241–6.

30. Custodio MR. Diagnostics for choosing between log-rank and Wilcoxon tests. Dissertations. 2007. Available from: https://scholarworks.wmich.edu/dissertations/895.

31. Ogura K, Miyamoto S, Sakuraba M, Fujivara T, Chuman H, Kawai A. Intercalary reconstruction after wide resection of malignant bone tumors of the lower extremity using a composite graft with a devitalized autograft and a vascularized fibula. Sarcoma. 2015;2015:861575.

32. Frisoni T, Cevolani L, Giorgini A, Dozza B, Donati DM. Factors affecting outcome of massive intercalary bone allografts in the treatment of tumours of the femur. J Bone Joint Surg Br. 2012;94(6):836–41.

33. Aponte-Tinajo L, Farfalli GL, Ritacco LE, Ayerza MA, Muscolo DL. Intercalary femur allografts are an acceptable alternative after tumor resection. Clin Orthop. 2012;470(3):728–34.

34. Errani C, Tsukamoto S, Almunhaisen N, Mavrogenis A, Donati D. Intercalary reconstruction following resection of diaphyseal bone tumors: a systematic review. J Clin Orthop Trauma. 2021;1(19):1–10.

35. Rappé M, Horodyski M, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop. 1993;286:241–6.

36. Mariscalco MW, Magnussen RA, Kaeding CC, Hewett TE, Flanigan DC. Nonirradiated versus irradiated Achilles allograft: in vivo failure comparison. Am J Sports Med. 2007;35(10):1653–8.

37. Mariscalco MM, Magnusson RA, Kaeding CC, Hewett TE, Flanigan DC. Use of irradiated and non-irradiated allograft tissue in anterior cruciate ligament reconstruction surgery: a critical analysis review. JBJS Rev. 2014;2(2):e4.

38. Costain DJ, Crawford RW. Fresh-frozen vs. irradiated allograft bone in orthopaedic reconstructive surgery. Injury. 2009;40(12):1260–4.

39. Aponte-Tinajo L, Ayerza MA, Muscolo DL, Farfalli GL. Survival, recurrence, and function after epiphysial preservation and allograft reconstruction in osteosarcoma of the knee. Clin Orthop. 2015;473(5):1789–96.

40. Gheradeghi M, Peivandi MT, Mazloomi M, Shoorin H, Hasani M, Seyf P, et al. Evaluation of clinical results and complications of structural allograft reconstruction after bone tumor surgery. Arch Bone Jt Surg. 2016;4(3):236–42.

41. Malinin T, Temple HT. Musculoskeletal tissue transplantation and tissue banking. 1st ed. New Delhi u.a: Jaypee Brothers Medical Pub; 2013. p. 268.

42. Bernd L, Sabo D, Zalhenn-Hinguraminec A, Niemeyer P, Daecke W, Simank HG. Experiences with vascular pedicled fibula in reconstruction of osseous defects in primary malignant bone tumors. Orthopade. 2003;32(11):983–93.

43. Abed YY, Beltrami G, Campanacci DA, Innocenti M, Scoccianti G, Capanna R. Biological reconstruction after resection of bone tumors around the knee: long-term follow-up. J Bone Joint Surg Br. 2009;91(10):1366–72.

44. Aponte-Tinajo LA, Ayerza MA, Muscolo DL, Farfalli GL. What are the risk factors and management options for infection after reconstruction with massive bone allografts? Clin Orthop. 2016;474(3):669–73.

45. Krieg AH, Davidson AW, Stalley PD. Intercalary femoral reconstruction with extracorporeal irradiated autogenous bone graft in limb-salvage surgery. J Bone Joint Surg Br. 2007;89(3):366–71.

46. Zimel MN, Czik AM, Rapp TB, Weissstein JS, Conrad EU. Megaprostheses versus condyle-sparing intercalary allograft: distal femoral sarcoma. Clin Orthop. 2009;467(1):281–24.

47. Rabitsch K, Maurer-Erd W, Pirker-Fruhaufl U, Wibmer C, Leithner A. Intercalary reconstructions with vascularised fibula and allograft after tumour resection in the lower limb. Sarcoma. 2013;2013:160295.

48. Li J, Wang Z, Guo Z, Chen GJ, Fu J, Pei GX. The use of allograft shell with intramedullary vascularized fibula graft for intercalary reconstruction after diaphyseal resection for lower extremity bony malignancy. J Surg Oncol. 2010;102(5):368–74.

49. Gundle KR. CORR Insights® do massive allograft reconstructions for tumors of the femur and tibia survive 10 or more years after implantation? Clin Orthop. 2020;478(3):525–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.